Palvella Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-04
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.06M.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $357.00K.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$222.00K, a 117.62% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $176.00K, a 31.34% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.36M, a 190.75% decline from fiscal 2024.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.50M.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$273.00K, a 120.10% decline from fiscal 2022.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.36M, a 56.94% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.42M 10-Q · filed 2026-08-04 | $1.20M derived: sum of 3 quarters · filed 2026-08-04 | $1.38M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $357.00K 10-Q · filed 2026-05-07 | $135.00K derived: sum of 2 quarters · filed 2026-05-07 | $311.00K derived: sum of 3 quarters · filed 2026-05-07 | -$188.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | -$222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$46.00K derived: sum of 2 quarters · filed 2026-03-31 | -$545.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.36M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $176.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$323.00K derived: sum of 2 quarters · filed 2026-08-04 | -$1.14M 10-Q · filed 2025-11-12 | $118.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | -$499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$1.32M 10-Q · filed 2026-08-04 | -$960.00K 10-Q · filed 2025-08-14 | -$58.00K derived: sum of 3 quarters · filed 2026-08-04 | $76.00K derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | -$819.00K 10-Q · filed 2026-05-07 | -$461.00K 10-Q · filed 2025-05-15 | $441.00K derived: sum of 2 quarters · filed 2026-05-07 | $575.00K derived: sum of 3 quarters · filed 2026-05-07 | $738.00K derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.39M derived: sum of 2 quarters · filed 2026-03-31 | $1.56M derived: sum of 3 quarters · filed 2026-03-31 | $1.50M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $297.00K derived: sum of 2 quarters · filed 2025-11-12 | $243.00K 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $109.00K 10-Q · filed 2025-08-14 | |||||
| 2024-03-31 | -$54.00K 10-Q · filed 2025-05-15 | ||||||
| 2023-12-31 | -$273.00K 10-K · filed 2025-03-31 | -$1.02M 10-K · filed 2024-03-29 | |||||
| 2022-12-31 | $1.36M 10-K · filed 2024-03-29 | ||||||
| 2021-12-31 | $3.15M 10-K · filed 2023-03-31 | ||||||
| 2020-12-31 | $500.00K 10-K · filed 2022-03-02 | ||||||
| 2019-12-31 | $679.00K 10-K · filed 2021-03-31 | ||||||
| 2018-12-31 | $3.94M 10-K · filed 2020-03-13 | ||||||
| 2017-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$2.34M derived: sum of 2 quarters · filed 2019-03-18 | -$1.98M derived: sum of 3 quarters · filed 2019-03-18 | -$1.90M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$804.76K derived: sum of 2 quarters · filed 2017-11-13 | -$723.61K 10-Q · filed 2017-11-13 | -$1.87M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2017-06-30 | $359.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $441.05K 10-Q · filed 2017-08-11 | -$700.81K derived: sum of 3 quarters · filed 2018-03-15 | $316.15K derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2017-03-31 | $81.15K 10-Q · filed 2017-05-15 | -$1.06M derived: sum of 2 quarters · filed 2018-03-15 | -$43.75K derived: sum of 3 quarters · filed 2018-03-15 | -$84.23K derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$124.90K derived: sum of 2 quarters · filed 2018-03-15 | -$165.38K derived: sum of 3 quarters · filed 2018-03-15 | $1.02M 10-K · filed 2018-03-15 | $1.02M 10-K · filed 2017-03-30 | ||
| 2016-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $976.48K derived: sum of 2 quarters · filed 2017-11-13 | $2.16M 10-Q · filed 2017-11-13 | $2.65M derived: sum of 4 quarters · filed 2017-11-13 | |||
| 2016-06-30 | -$40.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $1.14M 10-Q · filed 2017-08-11 | $1.63M derived: sum of 3 quarters · filed 2017-08-11 | $1.00M derived: sum of 4 quarters · filed 2017-08-11 | |||
| 2016-03-31 | $1.19M 10-Q · filed 2017-05-15 | $1.67M derived: sum of 2 quarters · filed 2017-05-15 | $1.04M derived: sum of 3 quarters · filed 2017-05-15 | $1.71M derived: sum of 4 quarters · filed 2017-05-15 | |||
| 2015-12-31 | $487.17K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$141.48K derived: sum of 2 quarters · filed 2017-03-30 | $528.68K derived: sum of 3 quarters · filed 2017-03-30 | $1.26M 10-K · filed 2017-03-30 | |||
| 2015-09-30 | -$628.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $41.51K derived: sum of 2 quarters · filed 2016-11-10 | $768.98K 10-Q · filed 2016-11-10 | $1.56M derived: sum of 4 quarters · filed 2016-11-10 | |||
| 2015-06-30 | $670.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $1.40M 10-Q · filed 2016-08-11 | $2.19M derived: sum of 3 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $727.48K 10-Q · filed 2016-05-12 | $1.52M derived: sum of 2 quarters · filed 2016-05-12 | |||||
| 2014-12-31 | $793.44K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $921.59K 10-K · filed 2016-03-23 | |||||
| 2014-09-30 | $128.15K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |